Procter & Gamble Health Ltd. (IN:PGHL)
:PGHL
Want to see IN:PGHL full AI Analyst Report?
Top Page
Procter & Gamble Health Ltd.
(PGHL)
Select Model
Select Model
Rating:73Outperform
Price Target:
₹5,697.00
▼(-0.95% Downside)
Action:ReiteratedDate:10/21/25
Procter & Gamble Health Ltd. demonstrates strong financial performance with robust profitability and a solid balance sheet, contributing significantly to the overall score. The technical analysis indicates mixed signals with short-term bearish momentum but a long-term bullish trend. The valuation is slightly high, reflecting growth expectations, but the attractive dividend yield provides a buffer. The absence of earnings call data and corporate events does not impact the score.
Positive Factors
Very strong balance sheet
Extremely low leverage and very high ROE provide durable financial flexibility. Minimal debt reduces refinancing and interest risk, allowing the company to fund marketing, R&D, or distribution expansion from equity and cash, and sustain operations through economic downturns without large liquidity strain.
Negative Factors
Gross margin pressure
A falling gross margin signals persistent input cost or mix headwinds that can erode long-term profitability if not offset by pricing or efficiency. For an OTC consumer healthcare player, sustained raw material or packaging inflation can compress margins and limit cash available for growth initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Very strong balance sheet
Extremely low leverage and very high ROE provide durable financial flexibility. Minimal debt reduces refinancing and interest risk, allowing the company to fund marketing, R&D, or distribution expansion from equity and cash, and sustain operations through economic downturns without large liquidity strain.
Read all positive factors
Procter & Gamble Health Ltd. (PGHL) vs. iShares MSCI India ETF (INDA)
Market Cap
₹85.93B
Dividend Yield3.28%
Average Volume (3M)310.00
Price to Earnings (P/E)30.5
Beta (1Y)0.55
Revenue Growth9.13%
EPS Growth4.38%
CountryIN
Employees1,336
SectorConsumer Defensive
Sector Strength42
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)46.74
Shares Outstanding16,599,382
10 Day Avg. Volume340
30 Day Avg. Volume310
Financial Highlights & Ratios
PEG Ratio1.37
Price to Book (P/B)15.96
Price to Sales (P/S)7.03
P/FCF Ratio51.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹6,800.00Price Target Upside18.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)219
Revenue Forecast (FY)N/A
Procter & Gamble Health Ltd. Business Overview & Revenue Model
Company Description
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemicals in India. It provides over-the-counter products, vitamins, minerals, and supplements. The company offers its products under the Polybion, Neurobion, Evion, Nasi...
How the Company Makes Money
PGHL primarily makes money by manufacturing (and/or sourcing) consumer healthcare products and selling them in India through trade channels such as pharmacies, chemists, modern retail, and distributors, generating revenue from the sale of finished...
Procter & Gamble Health Ltd. Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
80
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.84B | 12.18B | 11.51B | 12.30B | 11.14B | 10.09B |
| Gross Profit | 8.88B | 8.69B | 8.09B | 8.46B | 7.61B | 6.84B |
| EBITDA | 4.20B | 3.62B | 3.03B | 3.19B | 2.65B | 2.42B |
| Net Income | 3.07B | 2.51B | 2.01B | 2.29B | 1.93B | 1.77B |
Balance Sheet | ||||||
| Total Assets | 8.94B | 7.94B | 7.94B | 11.01B | 8.94B | 9.86B |
| Cash, Cash Equivalents and Short-Term Investments | 2.86B | 1.89B | 2.44B | 4.53B | 3.19B | 4.64B |
| Total Debt | 95.50M | 76.20M | 95.60M | 120.00M | 28.30M | 76.10M |
| Total Liabilities | 2.75B | 2.57B | 2.56B | 3.50B | 2.77B | 2.82B |
| Stockholders Equity | 6.20B | 5.37B | 5.38B | 7.51B | 6.16B | 7.04B |
Cash Flow | ||||||
| Free Cash Flow | 2.12B | 1.67B | 2.07B | 1.94B | 1.32B | 1.95B |
| Operating Cash Flow | 2.21B | 1.76B | 2.28B | 2.36B | 1.70B | 2.47B |
| Investing Cash Flow | 13.60M | 24.40M | -68.70M | -215.00M | -255.40M | -322.70M |
| Financing Cash Flow | -2.10B | -2.35B | -4.18B | -984.70M | -2.89B | -3.87B |
Procter & Gamble Health Ltd. Technical Analysis
Neutral
5751.70
Price Trends
4994.48
Positive
5315.89
Negative
5709.19
Negative
Market Momentum
-6.69
Negative
57.46
Neutral
79.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PGHL, the sentiment is Neutral. The current price of 5751.7 is above the 20-day moving average (MA) of 4875.09, above the 50-day MA of 4994.48, and above the 200-day MA of 5709.19, indicating a neutral trend. The MACD of -6.69 indicates Negative momentum. The RSI at 57.46 is Neutral, neither overbought nor oversold. The STOCH value of 79.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:PGHL.
Procter & Gamble Health Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹85.93B | 30.50 | ― | 3.28% | 9.13% | 4.38% | |
70 Outperform | ₹58.69B | 73.49 | ― | 1.43% | -23.87% | -11.81% | |
70 Outperform | ₹51.97B | 18.80 | ― | 2.03% | 2.07% | -0.98% | |
66 Neutral | ₹157.20B | -90.62 | ― | 0.28% | 31.45% | -36.34% | |
64 Neutral | ₹98.65B | 31.99 | ― | 1.24% | 1.90% | -8.15% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
55 Neutral | ₹23.70B | 80.19 | ― | 0.46% | 7.60% | -49.81% |
* Consumer Defensive Sector Average
IN:PGHL
Procter & Gamble Health Ltd.
5,109.10
72.46
1.44%
IN:EVEREADY
Eveready Industries India Ltd
323.20
2.21
0.69%
IN:JYOTHYLAB
Jyothy Labs Limited
262.65
-107.37
-29.02%
IN:SURYAROSNI
Surya Roshni Limited
237.95
-13.25
-5.27%
IN:SYMPHONY
Symphony Limited
873.55
-267.49
-23.44%
IN:ZYDUSWELL
Zydus Wellness Limited
489.40
137.85
39.21%
Procter & Gamble Health Ltd. Corporate Events
Procter & Gamble Health Posts Strong Q3 FY26 Results, Announces ₹160 Interim Dividend with Special Payout
Feb 6, 2026
Procter Gamble Health Limited reported unaudited financial results for the quarter ended 31 December 2025, with revenue from operations rising to ₹37,386 lakh and net profit for the quarter at ₹7,759 lakh, contributing to a nine‑...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.